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Introduction 
 
The unravelling of the physiology of the renin-
angiotensin system (RAS) started over 100 
years ago when in 1898 the Finnish physiolo-
gists Robert Tigerstedt and Per Bergman pub-
lished evidence that intravenous injection of 
rabbit kidney extracts raised blood pressure; 
they postulated that the substance responsible 
for this effect was a protein which they named 
renin [1]. It wasn’t until 1934 that Goldblatt 
showed in animal models that clamping of the 
renal arteries raised blood pressure [2] and in 
1938 Pickering described the partial purifica-
tion of renin and its ability to increase blood 
pressure [3]. In1940 Braun-Menendez and col-
leagues [4] and, independently Page and col-
leagues [5], proposed that renin itself was not 
directly responsible for its pressor effect but 
was in fact an enzyme. The names "hypertensin" 
and "angiotonin" were given independently to 
the pressor substance produced by the enzy-
matic action of renin. Subsequently, it was 
agreed that the term "angiotensin" would be 
used to describe this substance.  
 
In 1956, Elliott and Peart [6] and Skeggs and 
colleagues [7] discovered that the product of 
renin action was a decapeptide which actually 
required further enzymatic breakdown to form 
the active pressor substance, an octapeptide. 
The terms angiotensin I and  angiotensin II were 
introduced and the enzyme responsible was 
named angiotensin converting enzyme (ACE). 
Figure 1 illustrates the renin-angiotensin system 
and its physiological roles.  
 
It eventually became established that the RAS 
was involved in the homeostasis of fluid bal-
ance and blood pressure via effects on aldoster-
one secretion by the adrenal cortex and direct 
vasoconstriction.   The RAS was thus implicated 
in the aetiology of cardiovascular disorders (eg 
renal artery stenosis), and became the target of 
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research for antihypertensive medications.  
 
Since then, however, the role of the RAS in 
other aspects of physiology has been investi-
gated.  There is convincing evidence, for exam-
ple, that angiotensin II and its metabolites play 
an important role in the central nervous system 
and it has been implicated in aspects such as 
cognition, dementia, depression, anxiety and 
epilepsy [8, 9]. The brain RAS has recently, 
therefore, become the focus of studies targeted 
at the development of novel drugs for the treat-
ment of the above mentioned conditions. The 
RAS has also been implicated in the inflamma-
tory response, and with cancers [10]. 
 
To date, all drugs targeted at the RAS have simi-
lar aims: to decrease RAS function. It had been 
noted that venom from the Brazilian viper 
Bothrops jararaca caused severe hypotension 
as one of the effects of envenomation and in 
1965 it was found that the venom potentiated 
the effects of bradykinin [11]. This lead to the 
presumption that substances contained in the 
snake venom were inhibitors of kininase, an 
enzyme that had been described a few years 
earlier which inactivated bradykinin [11]; it was 
also found that peptides from the same venom 
Figure 1. A schematic representation of the renin-angiotensin system, its associated receptors and physiological ef-
fects. IRAP represents Insulin Regulated Amino Peptidase, the putative site of action of angiotensin IV; angiotensin IV 
inhibits its enzymatic activity. 
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were able to inhibit ACE [12]. Eventually medici-
nal chemists developed SQ14225 which later 
became known as captopril. Captopril and other 
ACE inhibitors are now first line drug therapies 
for the treatment of hypertension and heart fail-
ure. More recently an inhibitor of renin has been 
marketed, aliskiren, which similarly ultimately 
prevents the synthesis of angiotensin II and is 
also used as an antihypertensive medication.  
 
The other approach to pharmacological manipu-
lation of the RAS is to use antagonists of the 
angiotensin receptors. Early drugs such as 
saralasin were peptides which were non-
selective for AT1 and AT2 receptors, but modern 
drugs are metabolically-stable non-peptides 
with selectivity for the receptor subtypes, for 
example losartan.  
 
The focus of this review is the insertion / dele-
tion polymorphism of the gene encoding for 
ACE. The remainder will therefore focus on ACE 
and ACE inhibitors. 
 
ACE, ACE inhibitors and cardiovascular disease 
 
ACE inhibitors are first line therapies for the 
treatment of hypertension and heart failure. The 
current UK national guidelines for the treatment 
of hypertension (National Institute for Clinical 
Excellence, NICE) state that ‘In hypertensive 
patients younger than 55, the first choice for 
initial therapy should be an ACE inhibitor (or an 
angiotensin-II receptor antagonist if an ACE in-
hibitor is not tolerated). In hypertensive patients 
aged 55 or over, or black patients of any age 
(including both Black African and Black Carib-
bean patients, not Asian, Chinese, mixed-race, 
or other ethnic groups), the first choice for initial 
therapy should be either a calcium-channel 
blocker or a thiazide-type diuretic.’  
 
In addition, because administration of drugs 
such as ACE inhibitors which cause peripheral 
vasodilation results in a reduced cardiac work-
load, such drugs are routinely used for the relief 
of heart failure. The NICE guidelines for the 
treatment of heart failure give ACE inhibitors as 
the first-line treatment, but in this instance 
there are no additional considerations for age 
nor ethnic origin. The mechanism of action of 
the ACE inhibitors is heart failure is predomi-
nantly peripheral vasodilatory, but there is also 
evidence that the effect of reducing angiotensin 
synthesis also affects ventricular remodeling as 
a consequence of changes in AT2 receptor activ-
ity.  
 
The question of ethnic differences in responses 
to antihypertensive medication warrants further 
investigation. There is evidence that Black pa-
tients gain lower antihypertensive benefit from 
ACE inhibitors and beta-adrenoceptor antago-
nists (“Beta Blockers”) than other ethnic groups 
[13], with diuretics producing a greater de-
crease in systolic blood pressure in Black pa-
tients than ACE inhibitors [14]. In one study, one 
year therapy with the ACE inhibitor enalapril was 
associated with significant reductions in blood 
pressure amongst the White patients, but not 
amongst the Black patients [15]. Using cardio-
vascular consequences such as fatal and non-
fatal myocardial infarction and heart failure as 
end-points, NICE does not recommend the use 
of ACE inhibitors to treat hypertension in Black 
patients because ‘results of a subgroup analysis 
comprising Black patients from one randomised 
controlled trial (ALLHAT) indicated that therapy 
with the ACE inhibitor lisinopril was associated 
with a higher incidence of stroke (RR 1.40; 1.17
- 1.68 95% CI) and cardiovascular events (RR 
1.19; 1.09 - 1.3095% CI) compared to the thi-
azide-type diuretic chlorthalidone.’   
 
The case for ethnic differences in heart failure 
and its treatment are less clear. Black individu-
als are at much greater risk of heart failure than 
Whites: a 20-year prospective study of heart 
failure in over 5000 individuals recently re-
ported that heart failure developed in 27 indi-
viduals, all but one of whom were Black, mean 
age of onset 39 years [16]. By the age of 50, 
the incidence of heart failure was more than 10 
times greater in the Black men and women, 
than in the White. Amongst the Black patients, 
75% of the heart failure patients had developed 
hypertension before the age of 40. Earlier stud-
ies of ethnic differences in responses to treat-
ments for heart failure had produced conflicting 
responses. Exner et al [15] reported results 
from a study of 800 Black patients and almost 
1200 White patients over a period of nearly 3 
years showing that although there were no dif-
ferences in demographic variables, the Black 
patients had higher rates of death from any 
cause (12.2 vs. 9.7 per 100 person-years) and 
of hospitalization for heart failure (13.2 vs. 7.7 
per 100 person-years). Therapy with the ACE 
inhibitor enalapril was associated with a signifi-
cant decrease in the risk of hospitalization for 
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heart failure amongst the White patients but not 
in the Black patients. A meta-analysis of the 
available data, however, produced different re-
sults with ACE inhibitors being seen to reduce 
all-cause heart failure mortality in both Black 
and White patients [17]. ACE inhibitors and beta 
blockers (which act partially by decreasing renin 
secretion) are thus now considered as the es-
sential drugs to improve the prognosis of heart 
failure both in Blacks and Whites [18] 
 
Several hypotheses have been formulated to 
explain the increased risk of heart failure in the 
Black population and the failure of response to 
antihypertensive therapy with ACE inhibitors. 
Because the phenomenon was first observed in 
African Americans, one early hypothesis was 
that there was a naturally-selected ‘robust’ RAS 
as a consequence of mortality induced by dehy-
dration during the transport of African slaves to 
the US. More recent hypotheses, however have 
turned to gene polymorphisms, and the RAS in 
particular, and it is now become clear that the 
‘ethnic’ differences in cardiovascular risk and 
response to therapy may not be limited to ‘Black 
Africans’. This review concentrates on the inser-
tion / deletion polymorphism of the gene encod-
ing for ACE, and a literature review in late De-
cember 2009 indicated that there were over 
250 publications on the subject of this polymor-
phism in 2009 (January to December). The re-
view was conducted using ISI Web Of Knowl-
edge and the search terms ACE and Polymor-
phism.  As illustrated in Table 1, 250 publica-
tions on the subject of the ACE gene polymor-
phism in 2009 represents a decrease in the 
annual publication rate from a peak of approxi-
mately 600 per year between 1999 and 2003. 
This review will consider the recent (2009) pub-
lications only, for earlier reviews see Catellon 
and Hendi [19] and Jeunmaitre [20]. 
 
The insertion/deletion polymorphism of the ACE 
gene is defined as either the presence 
(insertion, I) or absence (deletion, D), of a 287 
base pair insert in intron 16 of the gene on 
chromosome 17q23 [21]. It is commonly de-
scribed by the rs number rs1799752, although 
it is also sometimes represented as rs4340, 
rs13447447 and rs4646994. The insertion 
appears to reduce ACE expression, thus DD ho-
mozygotes have 65% more, and ID heterozy-
gotes 31% more ACE than II homozygotes [22]. 
A meta-analysis of prevalence studies indicates 
that the overall frequency of the D allele is 54%, 
being unrelated to gender but there are ethnic 
differences[23], [24]. In Arab populations 
(Egyptians, Jordanians and Syrians) for exam-
Table 1.  The number of publications concerning the ACE gene I/D polymorphism since 1989  
 
Search Terms 1989-1993 1994-1998 1999-2003 2004-2008 
ACE polymorphism + Hypertension 11 351 682 596 
ACE polymorphism + Coronary 2 35 94 97 
ACE polymorphism + Infarct* 12 322 432 294 
ACE polymorphism + Kidney Disease - 85 244 172 
ACE polymorphism + Dementia - 4 28 33 
ACE polymorphism + Depression - - 12 12 
ACE polymorphism + Parkinson* - - 6 10 
ACE polymorphism + Inflam* 1 15 42 78 
ACE polymorphism + Asthma - 5 13 12 
ACE polymorphism + Diabetes - 152 289 244 
ACE polymorphism + Cancer - 4 11 58 
ACE polymorphism + Performance - 1 38 50 
Total 26 974 1885 1664 
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ple, frequencies of the D allele are approxi-
mately 65% [25]. Although there is evidence 
that an increase in ACE activity associated with 
the D allele does not result in increased synthe-
sis of angiotensin II [26], it might be expected 
that increased ACE activity would be associated 
with increased incidence of cardiovascular dis-
ease and resistance to ACE inhibitor therapy. 
 
Hypertension 
 
Recent studies of the association of hyperten-
sion with ACE genotype have shown a positive 
correlation of the D allele with hypertension in a 
south Indian population [27], and in a south 
China population [28], but not in Punjabi [29], 
juvenile American [30], Turkish [31] or Sardin-
ian [32] populations.   These findings suggest 
that in some populations, presumably in the 
face of various environmental variables, the D 
allele of the ACE gene, which elevates the activ-
ity of ACE, may be associated with hypertension. 
The correlation, however is not robust and in a 
sample of Brazilian women, the I allele has 
been seen to be associated with a systolic blood 
pressure elevated by approximately 11mmHg  
[33]. In the special case of gestational hyperten-
sion and pre-eclampsia, in a study undertaken 
in approximately 700 pregnant Italian women, 
of which 204 suffered from pre-eclampsia and 
56 from gestational diabetes, the D allele was 
significantly more prevalent in women suffering 
from mild pre-eclampsia than controls. There 
were no significant differences between gesta-
tional hypertension cases and controls [34]. 
 
 When considering the responses of hyperten-
sive patients to antihypertensive medications, 
that is, why Black patients show decreased re-
sponse to ACE inhibitors, the antihypertensive 
effects of a calcium channel antagonist, a beta-
adrenoceptor antagonist, a diuretic and an an-
giotensin receptor antagonist were all seen to 
be unaffected by ACE I/D genotype in White 
hypertensive men [35] and the same results 
were found for the same drug classes, including 
ACE inhibitors in Dutch patients [36]. No influ-
ence of the ACE genotype was found on the 
magnitude of the treatment-induced blood pres-
sure reduction in older Brazilian women [33] 
and 12-week therapy with the angiotensin re-
ceptor antagonist eprosartan has been seen to 
be associated with a good antihypertensive ef-
fect, regardless of ACE gene I/D polymorphism 
in Uzbek men [37]. The evidence is thus consis-
tent in that there is no association of ACE I/D 
genotype with response to antihypertensive 
therapy. Even when considering a common ad-
verse effect of ACE inhibitors, cough, no correla-
tion with ACE genotype has been found [38]. 
This polymorphism is therefore probably not 
responsible for the observed ethnic differences 
in responses to ACE inhibitors. 
 
It is well recognised that in healthy individuals, 
perturbations of blood pressure are normally 
rectified as part of the homeostatic processes, 
and indeed the RAS is perhaps the major ho-
meostatic process. It is perhaps, not surprising 
therefore that a single gene polymorphism asso-
ciated with increased activity of ACE, but proba-
bly no change in circulating angiotensin II [26], 
is not inevitably associated with increased inci-
dence of hypertension or decreased response to 
antihypertensive drugs. The effects of angio-
tensin on the heart, however, are more compli-
cated. Angiotensin, acting via AT1 receptors in-
duces vasoconstriction and salt retention, re-
sulting in increased blood pressure and there-
fore increased load on the heart.  Angiotensin, 
acting via AT2 receptors on the heart, however, 
has different effects: notably anti-apoptotic and 
anti-inflammatory. It might be therefore postu-
lated that increased ACE activity associated with 
a gene polymorphism might alter cardiac func-
tion. A recent study in Han Chinese patients 
with diastolic heart failure demonstrated that 
the concomitant presence of ACE DD and AT1R 
1166 CC genotypes synergistically increased 
the predisposition to the heart failure [39]. This 
finding is of interest as the AT1 gene polymor-
phism has no effect on receptor function or den-
sity, although it may alter sensitivity to angio-
tensin. 
 
Other cardiovascular disease 
 
The association of the ACE gene polymorphism 
with other aspects of cardiovascular pathology 
have been explored with conceivable justifica-
tion. There have recently been 3 studies of as-
sociation with coronary artery disease / stroke, 
all from Turkey, but with different authors. Two 
found no association between genotype and 
disease [31, 40], whilst the third found a higher 
frequency of the ACE D/D genotype in all pa-
tients than in the healthy population [41]. A 
meta-analysis of 58 studies concluded that 
there was no association between stroke and 
ACE genotype [42]; the Women’s Health Study 
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in 25,000 White US women similarly found no 
association of ACE gene I/D status and the inci-
dence of cardiovasular disease or stroke at the 
11 year follow-up [43]. 
  
Similarly for myocardial infarct (MI), no associa-
tion was found between ACE genotype and the 
disease in the US Women’s Health Study [43] 
nor in young Han Chinese patients [44]. Al-
though DD genotype was associated with higher 
risk of recurrent MI, life-threatening MI compli-
cations, and severe heart failure in a Russian 
population [45]. A study of sudden cardiac 
death in Russia revealed a decreased preva-
lence of II genotype amongst victims compared 
with the normal population [46], again suggest-
ing an adverse ‘effect’ of the D allele.  
 
Moving away from the coronary vasculature, to 
more peripheral vessels, the D-allele has been 
associated with a greater arterial stiffness as 
demonstrated by lower distensibility and higher 
pulse pressure [47]. The retinal arteriolar di-
ameter was also significantly narrower in sub-
jects with the DD genotype [48]. Paradoxical the 
frequencies of the D allele are also significantly 
higher in patients with aortic dissection, a condi-
tion involving separation of the arterial wall 
[49], although it has been reported that the ACE 
I/D gene polymorphism is not a susceptibility 
factor to aortoiliac occlusive disease. The poly-
morphism may, however, be an important factor 
in the development of abdominal aortic aneu-
rysm when coexisting with hypertension [50]. 
 
Still with blood vessels. It is suggested that that 
the DD genotype may be a risk factor for cere-
bral infarction in Han Chinese population [51]. 
Migraine is also a condition associated with 
changes in cerebrovascular haemodynamics: 
the US Women’s Health Study found no associa-
tion of ACEI/D status with migraine [43], al-
though in a smaller study of 150 migraine pa-
tients in Northern India, Joshi et al reported an 
increased prevalence of DD genotype amongst 
sufferers [52]. 
 
Kidney disease 
 
As described above, the physiology of the RAS 
was initially studied with respect to renal ho-
meostasis, it is not surprising, therefore, that it 
has been implicated in chronic kidney disease. 
In a small study in approximately 100 patients 
and controls in Southern India, Anbazhagan and 
colleagues reported that there was no associa-
tion of ACE I/D genotype with the disease [27]. 
In terms of treatment of the condition, however, 
there may be differences. In a small study in 93 
Japanese patients treated for approximately 3 
years with a combination of ACE inhibitors and 
angiotensin receptor antagonists, proteinurea 
decreased only in II, and ID individuals, not in 
DD, although there was no difference in the 
decrease in blood pressure between the two 
groups [53]. In a larger study in 1000 Italian 
patients, over 10 years, almost opposite find-
ings were reported, with ACE inhibitors realising 
greater health benefit in DD individuals than in 
II or ID [54]. Ironically the DD genotype has 
been associated with significantly poorer renal 
function in kidney transplant patients 18-30 
months following transplantation in German 
Caucasians [55]. 
 
In the specific case of diabetic nephropathy the 
frequency of the D allele and the DD genotype 
was significantly increased in Asian Indian pa-
tients compared with diabetic without neph-
ropathy and was associated with increased risk 
of nephropathy [56]; a similar higher frequency 
of the D allele was seen in Tunisian diabetic 
nephropathy patients [57]. Considering albu-
minurea as a correlate of nephropathy severity, 
in Iranian patients it has been reported that the 
frequency of the II genotype decreased and that 
of the DD increased with increasing severity of 
albuminurea and the D allele independently 
increased the odds of macroalbuminuria versus 
microalbumin [58]. In 435 Mexican patients 
there were no differences in ACE I/D genotype 
distribution between patients with and without 
albuminuria, although when the subgroup of 
female patients were studied separately, the DD 
genotype was more prevalent amongst albumin-
urea patients than those without albuminuria 
[59]. A meta-analysis concluded that II subjects 
had a 22% lower risk of diabetic nephropathy 
than D allele carriers, but that Asians (Chinese, 
Japanese, Koreans) derived greater protection 
(36%), than Caucasians (11%) [60]. 
 
The central nervous system 
 
In addition to roles in cardiovascular and renal 
homeostasis, the RAS has also been implicated 
in psychiatric and neurological conditions, with 
the use of ACE inhibitors to treat hypertension 
being seen to be associated with decreased 
depression and improved cognition. The ACE 
ACE I/D in health and disease  
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gene has therefore been an obvious candidate 
gene in studies of the aetiology of depression, 
dementia etc.  
 
Pandey et al reported a study of I/D allele distri-
bution between vascular dementia patients, 
degenerative dementia and age-matched con-
trols. No differences were seen between the 
groups [61]. A meta-analysis came to similar 
conclusions [62]. Results reported by Halbec-
que et al [63], and Miners et al [64] for Alz-
heimer’s Disease, a specific form of dementia, 
indicated a similar lack of association of the 
disease with ACE I/D genotype. Consideration of 
the association of the ACE gene I/D polymor-
phism and Alzheimer’s disease is still ongoing 
(see www.Alzgene)  
 
The association between ACE genotype and 
depression and suicide has also been explored 
recently. We have previously reported a lack of 
association between ACE genotype and depres-
sion in a Lebanese population [65]. A similar 
lack of association was more recently reported 
in a Finnish sample of treatment-resistant de-
pressed patients who were referred to electro-
convulsive therapy. The distribution of geno-
types and alleles did not differ between patients 
and healthy (non-depressed) controls nor did 
they influence response to treatment [66]. More 
recent studies have concentrated on suicide 
which is often used as a proxy measure of de-
pression. In a study in Caucasians, Fudalej et al 
reported an association of the I allele with de-
pression and a greater frequency of that allele 
amongst successful male and female suicide 
victims in comparison to age-matched controls 
[67]. Sparks et al, however, in a European sam-
ple, reported opposite results: in a study of 
‘suicide completers’, ‘suicide attempers’ and 
matched controls, the risk of suicide was signifi-
cantly associated with the DD genotype [68]. 
 
Harvey [69] recently suggested that depression 
may be a form of encephalopathy. Kehoe et al 
[70] have subsequently reported that the D al-
lele was significantly more frequent in Cherno-
byl clean-up workers who subsequently devel-
oped encephalopathy than those that did not.  
 
It has been known for some years that brain 
angiotensin affects dopamine, increasing con-
centrations in the nigrostriatal region, but not, 
or much less, the mesolimbic system [71]. An 
association of ACE gene I/D polymorphisms with 
Parkinson’s disease (nigrostriatal) would there-
fore be more likely than an association with 
schizophrenia (mesolimbic). No differences in 
ACE l/D genotype frequencies were found be-
tween between Italian Parkinson’s patients and 
controls [72], but the D allele was identified as 
a protective against schizophrenia in a Spanish 
population. The allele significantly reduced the 
risk of developing schizophrenia by 50%, the 
protection increased with the number of D al-
leles [73]. The association between the ACE 
gene I/D polymorphism and schizophrenia is 
under on-going consideration at SZgene 
(www.szgene.org). 
 
Inflammation 
 
Angiotensin has also been associated with a pro
-inflammatory effect [10], thus a genetic predis-
position to decreased angiotensin synthesis, eg 
possession of the ACE I allele, might be pre-
dicted to be associated with protection against 
inflammatory disorders. In the case of two de-
rmatological disorders, psoriasis and vitiligo, no 
association has been found between ACE I/D 
genotype and either condition in either Spanish 
or Turkish sufferers respectively [74], [75]. Simi-
larly, in Turkish patients, distribution of ID al-
leles was seen not to be associated with gener-
alised, aggressive periodontitis [76], although in 
the same population the frequency of the D al-
lele was significantly lower in a chronic perio-
dontitis group than in healthy controls [77]. 
 
In asthma, another inflammatory condition, the 
DD genotype has been seen to be more preva-
lent in both a Turkish and a Chinese sample 
[78], [79]. Whilst in the case of another inflam-
matory condition, pancreatitis, no significant 
differences were found in the prevalence of the 
ACE I/D genotype frequencies between patients 
with alcoholic, non-alcoholic, and acute pan-
creatitis and controls [80] [81]. Diabetes, how-
ever, presents a different story. In type I diabe-
tes, which is characterised by loss of pancreatic 
function, the D-allele was seen to be associated 
with severe hypoglycaemia requiring emergency 
treatment [82] and in type II diabetes, an asso-
ciation was seen with the D allele in a Tunisian 
population in both Arabs and Berbers [83], al-
though the same relationship was not seen in a 
Lebanese population [84], nor was there any 
association of genotype with insulin resistance 
in a very small study conducted in a Turkish 
population [85]. Metabolic syndrome in elderly 
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Slovaks and obesity in Saudi subjects were simi-
larly unassociated with ACE I/D genotype status, 
[86] and [87] respectively. 
 
Cancer 
 
There is a large body of work concerned with the 
possible association of the gene polymorphism 
with the incidence and progression of various 
cancers. The I/D genotype was less frequently 
associated with breast cancer in a study of 101 
Brazilian patients than were the DD or II geno-
types [88]. Meanwhile in colorectal cancer pa-
tients in a Romanian population the distribution 
of neither genotype nor alleles differed between 
cancer patients and controls [89]; the II geno-
type was more frequent in a sample of Greek 
and German oral squamous cell carcinoma pa-
tients than in matched controls [90]. 
 
A meta-analysis of gene polymorphisms associ-
ated with gastric cancer determined that the 
effects of the different ACE I/D genotypes dif-
fered between Asians and Caucasians [91], 
although it actually only included two publica-
tions concerning the ACE I/D polymorphism: the 
first which found no difference in the distribu-
tion of genotypes between Japanese patients 
and controls [92], and the second which found 
an greater frequency of DD genotypes amongst 
Caucasian gastric cancer patients [93]. 
 
Athletic performance 
 
A study of Japanese track athletes found that in 
males, but not females, the I allele was over-
represented amongst endurance athletes [94]. 
Similarly in Polish rowers the frequency of II was 
31% compared with normal controls where it 
was 19% [95].  In Spain, endurance runners 
were again found to have a significantly greater 
frequency of the I allele than professional foot-
ballers [96], proving that the relationship is with 
endurance sport, not physical fitness or 
strength alone. In Portuguese short distance 
elite swimmers, the D allele was more common 
than in controls and elite middle-distance swim-
mers [97], again demonstrating the link of the I 
allele with endurance. A possible mechanistic 
reason for the relationship was elucidated with 
the finding, in Asian rugby players, that the I 
allele confers advantages in aerobic capacity as 
determined by lung function tests [98]. 
 
This relationship, however, does not carry-over 
into the non-elite population. A Brazilian study 
of policemen undertaking a 17-week exercise 
programme found no influence of ACE gene I/D 
status on left ventricular hypertrophy following 
exercise [99] and in a study of tourists scaling 
Mount Kilimanjaro, the likelihood of success 
was not associated with ACE genotype [100]. In 
normal Korean women undertaking a 12-week 
exercise regime, however, those with DD geno-
type showed greater increase in intimal thick-
ness than the other two genotypes [101] and in 
elderly Japanese individuals, greater upper-body 
strength, as defined by grip strength etc, was 
associated with the DD genotype [102].  
 
A few studies have also been reported where 
there is no immediate reason for predicting an 
association with ACE genotype. A study of poly-
cystic ovary disease found no association [103], 
as did a study of spontaneous miscarriages 
[104]. No differences in gene frequencies were 
seen in normotensive individuals suffering ob-
structive sleep apnoea compared to normal 
controls, although the I allele was associated 
with mild to moderate obstructive sleep apnoea 
in hypertensive individuals [105]. Finally no as-
sociation between the polymorphisms and dif-
ferent ‘constitutions’ defined within an oriental 
medicine system [106]. 
 
Conclusions 
 
This review has concentrated on publications in 
2009 only, primarily to illustrate the extent to 
which associations are being sought between 
common gene polymorphisms and illnesses.  It 
should be remembered that approximately 55% 
of individuals carry the D allele, it is therefore 
unlikely that it will account for a large proportion 
of the variance associated with disorders affect-
ing perhaps less than 5% of the population.  
That being said, based on the publications of 
2009 is might be surmised that: The D allele 
carries with it an increased risk of hypertension, 
pre-eclampsia, heart failure, cerebral infarct, 
diabetic nephropathy, encephalopathy, asthma, 
severe hypoglycaemia in diabetes, gastric can-
cer (in Caucasians) and poor prognosis follow-
ing kidney transplant, On the positive side the D 
allele appears to offer protection against schizo-
phrenia and chronic periodontitis and confers 
greater upper-body strength in old age. 
 
The I allele, meanwhile, offers improved endur-
ance / athletic performance and aerobic capac-
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ity as determined by lung function tests, al-
though it does increase the risk of oral 
squamous cell carcinoma and obstructive sleep 
apnoea in hypertensives. 
 
Perhaps the final statement should come from 
Yang and colleagues, who, in a study in Han 
Chinese reported that there was no association 
between ACE gene I/D polymorphism and lon-
gevity [107]. 
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